Rapid Micro Biosystems, Inc. (RPID) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows mixed signals: while there are positive developments like the Millipore JV expansion and potential margin improvements, there are also concerns such as increased net loss, operating expenses, and management's reluctance to provide clear guidance on key issues. The Q&A reveals cautious optimism but also highlights uncertainties. The lack of strong catalysts and the mixed guidance suggest a neutral impact on the stock price over the next two weeks.
Key Financial Performance
Total Revenue $8 million, representing 11% year-over-year growth, driven by continued momentum across system placements and recurring revenue.
Product Revenue $5.6 million, increased 36% year-over-year, driven by strong consumable growth of more than 30% and higher system placements.
Service Revenue $2.4 million, decreased from $3.1 million in Q1 2025, due to timing of validation activities.
Recurring Revenue $5.1 million, increased 28% year-over-year, driven by strong growth across both consumables and service contract revenue.
Nonrecurring Revenue $2.9 million, decreased from $3.2 million in Q1 2025, primarily comprised of systems and validation revenue.
Gross Margin 5%, consistent with guidance, representing an 8 percentage point improvement from Q4 2025.
Product Margin Negative 8%, improved from negative 23% in Q1 2025, driven by a 33 percentage point improvement in consumable margins due to cost reduction activities, increased manufacturing productivity, and higher volumes.
Service Margin 34%, decreased from 43% in Q1 2025, due to lower service revenue, partially offset by productivity improvements.
Operating Expenses $14.2 million, increased from $12.1 million in Q1 2025, driven by R&D expenses ($3.4 million), sales and marketing expenses ($3.4 million), and G&A expenses ($7.4 million, including $0.9 million of severance and other nonrecurring corporate expenses).
Net Loss $14.3 million, increased from $11.3 million in Q1 2025, due to nonrecurring G&A costs, interest expense on debt, lower interest income, and higher noncash stock-based compensation expense.
Net Loss Per Share $0.31, compared to $0.26 in Q1 2025.
Cash Usage $15 million in Q1 2026, reflecting seasonal revenue and margin patterns, lower cash collections due to stronger Q4 2025 collections, and $0.9 million of severance and other nonrecurring corporate expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Growth Direct system placements: 6 systems placed in Q1 2026, with a total of 196 systems globally, including 160 fully validated systems. Expansion in Asia Pacific with placements in Singapore, Australia, and the first system in China.
Consumables: Record quarter with over 30% growth, driven by increased utilization in a growing installed base.
Asia Pacific expansion: Strengthened customer relationships and system placements in Singapore, Australia, and China. Hosted Japan Growth Direct Day event and engaged with customers in South Korea.
Collaboration with MilliporeSigma: Expanding Growth Direct placements in pharmaceutical and adjacent markets like personal care and medical devices. Entered a services agreement for exclusive validation and maintenance services.
Gross margin improvement: Q1 gross margin at 5%, an 8 percentage point improvement from Q4 2025. Full-year 2026 gross margin guidance at approximately 20%, with Q4 expected in the mid-20% range.
Cost reduction initiatives: Realized favorable pricing from suppliers, improved manufacturing efficiency, and supply chain optimization.
Long-term gross margin goal: Targeting 50%+ gross margins through internal initiatives and collaboration with MilliporeSigma.
Focus on automation and standardization: Promoting Growth Direct as an enterprise priority, supported by industry trends like increased automation and reshoring initiatives.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Technical Difficulties: The company experienced technical difficulties during the earnings call, which could impact investor confidence and communication efficiency.
Debt Obligations: The company faces challenges related to its existing and future indebtedness, which could impact its ability to operate effectively and meet financial obligations.
Service Revenue Variability: Service revenue showed quarter-to-quarter variability, primarily due to the timing of validation activities, which could lead to unpredictable financial performance.
Gross Margin Challenges: The company reported a low gross margin of 5% in Q1 2026, with product margins still negative, indicating ongoing cost structure and efficiency issues.
Cash Usage: The company used $15 million in cash during Q1 2026, its highest cash usage quarter, raising concerns about cash flow management and sustainability.
Regulatory Pathways in China: While the company placed its first system in China, evolving regulatory pathways could pose challenges to market entry and expansion.
Nonrecurring Expenses: The company incurred $0.9 million in severance and other nonrecurring corporate expenses, impacting its financial performance.
Interest Expense: The company faces higher interest expenses due to debt issued in Q3 2025, which could strain financial resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company reaffirmed its full-year 2026 revenue guidance of $37 million to $41 million, including 30 to 38 system placements.
Second Quarter 2026 Revenue Guidance: Revenue is expected to be at least $7.7 million, including at least 4 system placements.
Gross Margin Projections: For Q2 2026, gross margin is expected to be in the mid- to high teens. For the full year, total gross margins are projected to be approximately 20%, with a Q4 exit rate in the mid-20% range or better. Product margin is expected to be in the high single digits to low teens, and service margin above 40%.
Validation Activities: The company expects to complete at least 25 validations in 2026.
Operating Expenses: Full-year operating expenses are projected to be between $48 million and $52 million, with $8 million in noncash expenses.
Capital Expenditures: Capital expenditures for 2026 are expected to be $2 million.
Cash Usage and Liquidity: Cash usage is expected to decline sequentially each quarter in 2026. The company has $23 million in existing cash and $25 million of remaining availability under its Trinity Capital credit facility.
Long-Term Gross Margin Goals: The company remains focused on achieving long-term gross margins of 50% or higher through internal initiatives and collaboration with MilliporeSigma to reduce costs.
Market Trends and Strategic Focus: The company is leveraging favorable industry tailwinds, including increased automation, U.S. reshoring initiatives, and the growing complexity of advanced biomanufacturing, to enhance its visibility into its longer-term commercial pipeline extending into 2027 and 2028.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the Millipore JV expansion and the services involved?
A:The agreement is linked to Growth Directs that MilliporeSigma sells, and the company will provide all associated services, including installation, qualification, and routine use services. Service revenue will be recorded by the company, and they will perform all installation and qualification services globally, whether through their direct channel or MilliporeSigma's channel.
Q:Is the scale on consumables related to needing more volume or solving technical issues on the Millipore side?
A:It is a combination of both. There is an opportunity to work with MilliporeSigma to source consumables over time, which is expected to drive margin improvement. Currently, the company does not source consumables from MilliporeSigma, but they have expertise in the product and are expected to increase volume and growth.
Q:What are the terms of the $25 million line of credit remaining available?
A:The $25 million line of credit consists of two tranches and an additional $5 million at the lender's option. The first tranche of $10 million is expected to be available by the end of the year, contingent on meeting financial metrics. The second tranche of $10 million could be unlocked by mid-2027. The additional $5 million is unallocated and could be unlocked with the lender's agreement.
Q:Is the 30-plus percent growth in consumables this quarter part of an acceleration trend or episodic?
A:The growth is attributed to the continued expansion of the Growth Direct footprint, efficiencies in validation, and customers using the systems to drive ROI. Discussions with customers are becoming more strategic, and there is increasing interest in enterprise-wide automation and integration of automation technology.
Q:What portion of the 30 to 38 systems for the year comes from existing orders, and how much new business is needed?
A:The company feels good about the funnel and the range of 30 to 38 systems, which includes contributions from MilliporeSigma. There is variability in the range, and opportunities exist to drive movement within it through large multisystem orders and MilliporeSigma's commitments. However, the company did not comment on additional Samsung placements after Q1.
Q:How should we think about the impact of consumables and services revenue on margins over the coming quarters?
A:Consumable margins are expected to improve in the second half due to increased volume, material cost reductions, and vendor pricing reductions. Service revenue is expected to be higher in the second half, driven by validations from systems placed in Q4 of the previous year.
Q:Do you expect any notable changes in cell and gene therapy programs due to the recent FDA leadership overhaul?
A:The company actively monitors FDA approvals and has high penetration in the cell therapies CAR-T market. They have not observed any significant changes in approval momentum recently but remain well-positioned to win business in the cell and gene therapy market globally.
Q:Can you characterize the Millipore sales funnel and their focus on industrial verticals?
A:The Millipore sales funnel is growing globally, with a focus on the broader pharmaceutical markets. MilliporeSigma has hired specialists in North America, Europe, and Asia, and their relationships are deepening. They also have the potential to expand into other verticals like personal care, cosmetics, and medical devices, which expands the company's total addressable market.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding additional Samsung placements after Q1, stating that they could not comment on whether further placements would occur this year.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amgen North
Asia Pacific
Australia addition
Biologics success
Biosystems delay
COO Director
China investment
Communications Shannon
Day event
Direct Day
Direct deployment
Direct enterprise
Direct system
Director afternoon
Investor Relations
Japan Direct
Japan South
Korea QC
Micro provider
Micro system
MilliporeSigma Rapid
base
biopharma
collaboration MilliporeSigma
discussion
driver
engagement
framework
leverage
momentum
overview priority
peer
platform
region
therapy
visibility
RPID Transcript
Rapid Micro Biosystems, Inc. (RPID) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call shows mixed signals: while there are positive developments like the Millipore JV expansion and potential margin improvements, there are also concerns such as increased net loss, operating expenses, and management's reluctance to provide clear guidance on key issues. The Q&A reveals cautious optimism but also highlights uncertainties. The lack of strong catalysts and the mixed guidance suggest a neutral impact on the stock price over the next two weeks.
Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call presents a mixed outlook. Positive aspects include increased consumable and recurring revenue, raised revenue guidance for 2025, and promising partnerships. However, concerns arise from inventory charges impacting margins, a widening net loss, and vague management responses in the Q&A. The lack of specific data on CDMO placements and Samsung orders adds uncertainty. While there are growth drivers, the immediate financial health and unclear guidance temper expectations, resulting in a neutral sentiment.
Rapid Micro Biosystems, Inc. (RPID) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
Rapid Micro Biosystems, Inc. (RPID) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call revealed positive signs such as a guidance raise due to a large multi-system order, consistent global demand, and improved service margins. Despite a net loss, operating expenses decreased, and cash reserves are strong. The MilliporeSigma partnership and high ROI investments further bolster the outlook. However, management's lack of clarity on some order specifics and onshoring timelines tempers enthusiasm. Overall, the positive factors outweigh the negatives, suggesting a stock price increase in the near term.
RPID Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
